Biodesix Q3 2023 EPS $(0.14) Beats $(0.15) Estimate, Sales $13.49M Miss $14.36M Estimate
Portfolio Pulse from vinayak@benzinga.com
Biodesix (NASDAQ:BDSX) reported Q3 2023 earnings per share (EPS) of $(0.14), beating the analyst consensus estimate of $(0.15) by 6.67%. However, the company's quarterly sales of $13.49 million missed the analyst consensus estimate of $14.36 million by 6.05%. Compared to the same period last year, the EPS increased by 58.82% and sales increased by 21.46%.
November 07, 2023 | 9:15 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Biodesix's Q3 2023 EPS beat estimates, but sales missed. This mixed result could lead to uncertain short-term price movements.
Biodesix's EPS beat estimates, which is a positive signal for investors. However, the company's sales missed estimates, which could be a concern. This mixed result could lead to uncertain short-term price movements.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100